Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Generics Market Continues To Seek Stability

Firms Adopt Varying Strategies To Ride Out Ongoing Turbulence In The US

Executive Summary

As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

You may also be interested in...



Mayne Pharma Pursues ‘Aggressive Rationalization’ To Rally Revenue

Mayne’s 2022 results take stock of pivotal changes, with the Australian firm drawing down its generics portfolio as it focuses on the US branded products market. These new priorities come amid a high-value asset sale and a change in CEO.

Sandoz Sees Room For Improvements To US Market

Overcoming residual negative perceptions around generics, reforming Medicaid and Medicare policies that unfairly penalize generics and ensuring that “skinny label” generics can continue to be marketed are among the key priorities for Sandoz in the US, Carol Lynch, president of Sandoz Inc. and head of North America, tells Generics Bulletin in an exclusive interview.

Upsher-Smith Launches Three New Generics

Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel